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ABSTRACT
Autologous stem cell transplant (ASCT) has been shown to be an effective treatment for follicular lymphoma
(FL). We explored our experience in ASCT for FL among all patients treated over a 15-year period from
diagnosis through their entire treatment history including relapse post ASCT. All patients who underwent an
unpurged ASCT for relapsed, advanced FL between June 1990 and December 2000 were analyzed. After
salvage therapy they received melphalan/etoposide/total body irradiation, BCNU, etoposide, cytarabine, mel-
phalan (BEAM), or cyclophosphamide/BCNU/etoposide (CBV) as conditioning for the ASCT. One hundred
thirty-eight patients with a median age of 48 years and a median follow-up of 7.6 years were analyzed. The
majority were of the subtype grade 1, nontransformed (FL-NT), having had 1 prior chemotherapy. The
progression-free (PFS) and overall survival (OS) of the FL-NT at 10 years were 46% and 57%, respectively, and
at 5 years for the transformed (FL-T) were 25% and 56%, respectively, of which only the PFS was significantly
different (P  .007). The median OS from diagnosis was 16 years for the FL-NT. ASCT positively altered the
trend of shorter remissions with subsequent chemotherapies, and there was no difference in OS between those
who had 1, 2, or >2 chemotherapies prior to ASCT. Salvage therapy for relapse post ASCT was effective (OS
>1 year) in a third of patients. Unpurged ASCT is an effective tool in the treatment of relapsed, aggressive
FL-NT and FL-T, is superior to retreatment with standard chemotherapy, is effective at various stages of
treatment, is likely to have a beneficial influence on the natural history of this disease, and the disease is
amenable to salvage therapy post-ASCT relapse.
© 2007 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Follicular lymphomas (FL) are a group of non-
odgkin’s lymphomas (NHL) with an indolent
ourse [1]. Traditionally, treatment has consisted of
hemotherapy and/or radiotherapy, [2] and the overall
urvival (OS) has been shown to range from 7 to 10
ears [3]. Until recently, no therapy has been superior
o another, in terms of OS from a “watch and wait” to
n intensive combination chemotherapy approach
4-11]. Once treatment is initiated, the ﬁrst remission
asts 1-3 years and the OS is 4-5 years. Subsequent d
56emissions become shorter with each additional
ourse of treatment [4,12-14]. Finally, in about 20%-
0% of patients the lymphoma may transform to a
igher grade lymphoma (FL-T) which carries a
oorer prognosis [13,15,16].
Autologous stem cell transplants (ASCT), follow-
ng high doses of chemotherapy and/or radiotherapy,
ere introduced as a strategy to salvage patients who
ad relapsed from conventional chemotherapy. Dose
ntensiﬁcation has been shown to be effective in many
tudies in other lymphomas [17-20], illustrating the
irect relationship between the dose of a given che-
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A 15-Year Analysis of Early and Late Autologous HSCT 957otherapy and the ultimate response [21]. Several
roups have, more recently, reported on their experi-
nce with ASCT, generally conﬁrming that ASCT
ppears to have a positive impact upon the natural
istory of the disease [22-31].
In phase II studies, ASCT has been demonstrated
o be valuable in the relapsed setting producing supe-
ior survival outcomes than would be expected from
onventional chemotherapy [28,31]. Some of these
roups have attempted to use a purged stem cell prod-
ct, which is negative by the polymerase chain reac-
ion (PCR) at transplant. These groups have shown
hat there appeared to be a lower risk of relapse in
hose who were able to be purged, usually with a
ariety of monoclonal antibodies (mAb), of the marker
ene; however, it is not clear if a survival advantage
as been demonstrated over an unpurged stem cell
roduct [23,25,28,32].
Attempts have been made to try and apply the
uccesses seen in treating the follicular nontrans-
ormed lymphomas (FL-NT) to the more dismal sit-
ation where transformation has occurred. In general,
hey appear to continue to have a poorer outcome as
emonstrated by several studies [33-35]. However, a
ore recent survey by the EBMT suggested that a
ubset of FL-T patients may beneﬁt from such inten-
ive therapy [36].
Salvage therapy for many diseases for relapse post-
SCT such as in acute leukemia and aggressive lym-
homa is traditionally thought of as fruitless as few
atients can achieve prolonged remissions. However,
here are at least 2 reports examining, primarily, this
uestion in FL. Both indicated that there is a subset of
atients in whom salvage therapy is useful producing
rolonged remissions [37,38].
In this paper, we describe our large cohort, pri-
arily within a local community of unselected pa-
ients with relapsed aggressive FL treated with an
npurged ASCT from diagnosis through the natural
istory of their disease.
ATIENTS AND METHODS
atient Groups
This study includes all patients referred to the
ttawa Hospital’s Blood and Marrow Transplant
rogram (TOH-BMT), a regional tertiary care refer-
al center (between June 1990 and December 2000)
ith relapsed aggressive FL (FL-NT or FL-T) who
eceived an ASCT. All had failed or progressed after at
east 1 course of chemotherapy. Follow-up of the
atients continued through to the end of December
005.
alvage Therapy prior to ASCT
Patients received at least 1 course of salvage che-
otherapy with either CHOP, DHAP, or mini- cEAM (BCNU, etoposide, cytarabine, cyclophos-
hamide). Patients with insufﬁcient disease control
50% reduction in the initial mass) after at least 2 of
hese regimens were classiﬁed as chemotherapy-insen-
itive (CIS). Those that responded were classiﬁed as
hemotherapy-sensitive (CS).
tem Cell Collection
Stem cells were collected by bone marrow harvest
nd/or a peripheral blood stem cell (PBSC) collection
o achieve a target of 2.5  106 CD34 cells/kg,
sually following the second cycle of salvage chemo-
herapy. Filgrastim (G-CSF [300 g if 70 kg and
80 g if 70 kg]) was introduced in the collection
egimen after July 1992. It was used for at least 10 days
ollowing the second chemotherapy regimen and con-
inued until completion of the stem cell harvest (10-12
ays). Prior to June1993 most ASCTs were completed
sing bone marrow. After March 1994, PBSC collec-
ions were almost exclusively used.
onditioning Regimens
Patients with FL-NT were treated with a combi-
ation of etoposide (60 mg/kg i.v. day 2) melphalan
140 mg/m2 i.v. day 1), and total body irradiation
TBI) (day 0). Patients who were judged to be FL-T,
ither on rebiopsy or because of a rapid clinical change
uch as rapidly growing lymph nodes, increasing lac-
ate dehydrogenase, or systemic symptoms that had
ot been previously present were treated with BEAM,
fter September 1997 [39,40]. Prior to this date they
ere treated with CBV.
The dose of TBI used was 1200 cGy in 6 fractions
rior to September 1992, and was subsequently
hanged to 500 cGy in a single fraction Therefore,
ost patients in the FL-NT group had a lower dose of
BI, as this was reduced early in the cohort to mini-
ize toxicity and none of the FL-T were treated with
adiation.
Unpurged bone marrow (BM), PBSC, or both was
hen reinfused. PBSC were favored over BM in the
L-NT group, as this has become the preferred stem
ell product over the past decade [41].
ollow-up
Disease progression was monitored by members
f TOH-BMT or the referring hematologist every 3
onths with CT scans for the ﬁrst 2 years and then
-3 times/year.
tatistics
We evaluated baseline characteristics of the de-
cribed cohort of patients by computing appropriate
easures of frequency, central tendency, and dispersion
or risk factors of interest. Baseline characteristics were
ompared for differences using the chi-square analysis
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M. Sabloff et al.958or categoric variables and the Mann-Whitney test for
ontinuous variables. Subsequently, the inﬂuence of
hese risk factors on duration of both progression-free
PFS) and OS in FL-NT patients was evaluated using
aplan-Meier plots and log-rank statistics to perform
nivariate assessments, and Cox Proportional hazards
odeling to perform multivariable assessments. The
ollection of risk factors considered in this investiga-
ion included the following: age at BMT (40 years
ersus 40 years), sex, number of chemotherapies
rior to salvage, and blood and marrow transplanta-
ion (BMT) (1, 2, 2), product received (PBSC, mar-
ow, or both), TBI dosage (500 cGy/1 fraction versus
200 cGy/6 fraction), diagnosis (FL grade 1, 2, 3),
hemosensitivity status, duration of time between di-
gnosis, and BMT (6 months, 6 months to 1 year,
1 year), and duration of time between ﬁnal chemo-
herapy session and BMT (6 months, 6 months to 1
ear, 1 year). A statistical signiﬁcance level of 5%
as chosen for all tests, and 95% conﬁdence intervals
ere computed for all hazard ratios estimated in the
ultivariable analysis.
Adverse outcomes such as relapse, deaths, treat-
ent-related mortality (TRM) (ie, all deaths 100
ays post-ASCT unrelated to disease progression),
able 1. Patient Characteristics
Characteristics FL-NT FL-T
ubjects 115 23
edian overall age (years) range 48 (22-62) 49.6 (30-65)
edian follow-up of survivors
(years) range 7.7 (1.1-13.8) 7.6 (6.1-9.6)
ex
Male 71 13
Female 44 10
ubtype
Grade 1 74 9
Grade 2 36 8
Grade 3 5 4
Undefined 1 1
edian duration of first
remission (years) range 1.2 (0-8.2) 0.6 (0-5.8)
edian time from diagnosis to
ASCT (years) range 2.8 (0.5-15) 3.6 (0.3-20)
BI dose (Gy)
500 cGy/1 fraction 95 0
1200 cGy/6 fractions 20 0
tem cell source
PBSC 73 16
BM 22 0
Both 20 7
umber of prior chemotherapies
1 61 11
2 29 7
>2 25 5
BSC indicates peripheral blood stem cells; ASCT, autologous stem
cell transplant; TBI, total body irradiation; FL-NT, follicular lym-
phoma—nontransformed; FL-T follicular lymphoma—trans-
formed; BM, bone marrow.econdary malignancies, nonrelapse mortality (NRM)ie, all deaths unassociated with relapse or TRM),
ere calculated as absolute percentages.
All statistical analyses were carried out using SAS,
ersion 8.1 (SAS Institute, Cary, NC).
ESULTS
atient Population
A total of 138 patients, between the ages of 22 to
5 years, had an ASCT between June 1990 and De-
ember 2000. The majority of the patients were male
nd initially diagnosed as follicular grade I. The de-
ographics of this population are shown in Table 1.
he median length of follow-up from ASCT was 7.7
ears for FL-NT and 7.6 years for FL-T. Because the
edian duration of the ﬁrst remission was 1 year,
uch shorter than the typical 2.5 years, the cohort was
escribed as an “aggressive” FL [13,14,28].
utcome post-ASCT
Patient outcomes are presented in Table 2. The
stimated OS and PFS, as outlined, in Table 3, of the
L-NT at 10 years post-ASCT was 57% and 46%,
espectively. The OS and PFS at 5-years for the FL-T
as 56% and 25% (Figure 1A and B).
The median OS from diagnosis is 16 and 11 years
or the FL-NT and FL-T groups, respectively (Figure 2).
The relapse rate was 37% and 74%, for FL-NT
nd FL-T, respectively. There was a similar propor-
ion of deaths among the 2 groups (40% and 43%).
he NRM was not signiﬁcantly different between the
groups, nor was the TRM. Long-term toxicity in the
orm of developing either another malignancy or my-
lodysplasia post transplant was 7% in the FL-NT
roup and 18% in the FL-T.
able 2. Outcomes Post-ASCT
FL-NT
(%)
FL-T
(%) P Value
dverse events post-ASCT
Relapse 43 (37) 17 (74) .002
MDS 5 (4) 2 (9) NS
Adenocarcinoma/cancer 4 (3) 2 (9) NS
ortality post-ASCT
Total number of deaths 46 (40) 10 (43) NS
TRM (<100 days) 3 (3) 0 (0) NS
NRM 16 (14) 1 (4) NS
RM indicates treatment-related mortality (i.e., death within 100
days of ASCT that was not resulting from disease progression);
MDS, myelodysplasia; NRM, nonrelapse mortality (ie, all deaths
not resulting from disease progression or TRM, including those
fromMDS, malignancy or other [ie, stroke, sepsis, cardiac arrest,
pulmonary ﬁbrosis, and suicide]); FL-NT, follicular lym-
phoma—nontransformed; FL-T, follicular lymphoma—trans-
formed; NS, not signiﬁcant.
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A 15-Year Analysis of Early and Late Autologous HSCT 959ffect Number of Previous Therapies on Outcome
Among the many therapies that these patients are
ubjected to along their treatment course, an attempt
o elucidate the inﬂuence of ASCT was carried out by
omparing the interval between therapies. Patients
ere divided up by the number of standard chemo-
herapies prior to ASCT (1, 2, or 2), and Kaplan-
eier curves were constructed illustrating the time to
ext treatment (TTNT) between the chemotherapies
nd the PFS after ASCT. As shown in Figure 3A-C, a
imilar trend is seen, most notably that with successive
umber of standard chemotherapies the remission du-
ation is shorter; however, post-ASCT the PFS was
uch longer than the previous TTNT. Although we
re comparing 2 different measures (TTNT and
FS), the TTNT is generally more prolonged than
he PFS, as patients are usually monitored beyond the
ime that progression of disease is noted to the time
hat another therapy is indicated; therefore, this anal-
sis should underestimate the difference between dis-
ase progression pre- and post-ASCT.
The timing of ASCT has also been debated, some
rguing for earlier versus later intervention [42-45].
o attempt to address this issue the PFS from each of
hese groups (1, 2,2 prior chemotherapies) was then
ompared to assess if there was any difference in PFS
f ASCT was performed earlier or later in the treat-
ent course. As shown in Figure 4A the PFS from the
bove analysis is not signiﬁcantly different. Further
able 3. Progression-Free and Overall Survival Outcomes Based on In
OS from ASCT (%)
5 Years 10 Years
L-NT 72 57
L-T 56
L-NT
Age (years)
<40 96 79
>40 65 50
Histology
Grade 1/2 74 58
Grade 3 40
TBI dose (cGy)
500 cGy/1 fraction 69 52
1200 cGy/6 fractions 85 75
Stem cell Source
BM 82 72
PBSC 70 57
Both 65 44
# CT
1 73 63
2 75 62
>2 67 42
Chemosensitivity
CS 75 59
CIS 29 —
S indicates overall survival; PFS, progression-free survival; FL-N
transformed; TBI, total body irradiation; PBSC, peripheral bloo
sitive; ASCT, autologous stem cell transplant; BM, bone marrow.he OS between these 3 groups (Figure 4B) is not
igniﬁcantly different either from ASCT (P  .41) or
rom diagnosis (P  .88, not shown). Therefore, it
oes not appear that ASCT must be done earlier in
he treatment course to be maximally effective.
utcomes Once Relapsed after ASCT
We ﬁnally examined the course of those who re-
apsed post-ASCT. Among the 43 of 115 (37%)
L-NT and 17 of 23 (74%) FL-T, patients who re-
apsed post-ASCT the median time from ASCT to
elapse was 1.3 and 0.9 years, respectively. This is in
eeping with previous observations by others demon-
trating a median time to relapse of 11-14 months
37,38]. Salvage therapy post-ASCT was provided to
9 of 43 (67%) FL-NT and 13 of 17 (76%) FL-T
atients using any 1 or combinations of the following
reatments: Radiation, chemotherapy, rituximab, allo-
eneic stem cell transplant, node removal, or support-
ve care. OS and PFS from salvage therapy are illus-
rated in Figure 5. No single therapy stood out as
ore beneﬁcial in this setting, including rituximab
nd allogeneic stem cell transplant. Although more
atients who lived longer than 1 year received either
ituximab or an allogeneic stem cell transplant com-
ared to those who did not survive 1 year this result
as not statistically signiﬁcant.
Although, there was a signiﬁcantly greater number
f patients in the FL-NT compared to the FL-T
Characteristics
P Value
PFS after ASCT (%)
P Value5 Years 10 Years
.33 56 46
.00725
.003 77 60
.0852 44
.12 59 47
40 40 .3
.11 56.1 40.4
.0475 70
.45 77 68
.11
58 46
45 31
.48 63.6 53
.66
50.1 46
59.3 37
.01 62 50
<.000114 —
icular lymphoma—nontransformed; FL-T, follicular lymphoma—
cells; CT, chemotherapy; CS, chemosensitive; CIS, chemoinsen-dividual
T, foll
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M. Sabloff et al.960roup who received chemotherapy over radiation,
hich might imply that the FL-NT were treated more
ggressively, their OS were similar, with approxi-
ately 30% achieving a prolonged remission. Pres-
ntly, 13 FL-NT patients and 5 FL-T patients are
live 1-11 years and 2-7 years, postrelapse after
SCT, respectively.
igure 1. Survival from ASCT between the FL-NT and the FL-T.
, Overall survival (OS) [FL-NT versus FL-T, P  .33]; B, Pro-
ression-free survival (PFS) [FL-NT versus FL-T, P  .007].mFigure 2. Overall survival (OS) from diagnosis P  .25.rognostic Factors Prior to ASCT
redicting Survival
Univariate and multivariate analyses on survival
utcomes were performed for the FL-NT group.
nivariate analysis using Kaplan-Meyer plots and log-
ank statistics demonstrated that chemosensitivity
P  .01) and age 40 (P  .01) were positive pre-
ictors of survival.
Multivariate analysis cox proportional hazards
igure 3.Comparison between the time to next treatment (TTNT)
rior to ASCT and PFS post ASCT: A, After 1 chemotherapy (CT);
, after 2 CT; C, after 2 CT.odeling also identiﬁed chemosensitivity (P  .01)
a
v
w
t
a
o
D
g
t
s
t
w
y
t
c
s
p
t
d
m
F
n
t
s
r
s
g
d
r
m
q
o
s
e
c
o
t
n
n
t
F
t
N
F
r
F
f
A 15-Year Analysis of Early and Late Autologous HSCT 961nd age 40 (P  .02) as positive predictors of sur-
ival. In addition, when time was taken into account
ith respect to the TBI survival curves, this interac-
ion term between TBI dosage and time demonstrated
positive effect with higher dose (P  .03), as dem-
nstrated in Figure 6.
igure 4. Survival from ASCT based on prior number of chemo-
herapies (CT). A, progression-free survival. B, Overall survival.
either is statistically signiﬁcant.
igure 5. Overall survival from relapse post-ASCT of those who
welapsed postASCT.ISCUSSION
ASCT for FL has been investigated by many
roups in an attempt to demonstrate its role in the
reatment of FL and at what point such a treatment
hould be introduced [23-25,27,28,30,43]. PFS, in
hese studies, ranged between 42% and 63%, and OS
as estimated to be between 65% and 84% at 4-9
ears. However, because of the long natural history of
his disease, it has been difﬁcult to present consistent
onvincing evidence that ASCT has had an impact on
urvival outcomes.
Our analysis of a 15-year follow-up of a cohort of
atients with “an aggressive,” relapsed FL after being
reated with an unpurged ASCT using a uniform con-
itioning regimen further adds strength to the argu-
ent that ASCT is an effective therapy for relapsed
L. Through this cohort we have evidence that the
atural history has had an impact on such intensive
herapy in terms of the median survival from diagno-
is, which is 16 years, longer than the 7-10 years
eported with conventional therapy. This trend is also
upported by results from others such as Freedman’s
roup who reported an OS of 69% at 12 years from
iagnosis [28].
The stubbornness of this disease to remain in
emission after most therapies has been well docu-
ented, and that once relapse has occurred subse-
uent remissions tend to be shorter than the previous
ne. We demonstrate here that this trend does not
eem to apply to ASCT, and that there was no differ-
nce in OS among those who had 1, 2, or 2 prior
hemotherapies (Figures 3 and 4B), either from ASCT
r from diagnosis [14,24,31]. Therefore, it appears as
hough ASCT can overcome some of the refractori-
ess of the disease, without losing too much effective-
ess with later relapses, contrary to previous publica-
ions [43,46,47].
This cohort also highlights that those patients
igure 6. Overall survival comparing dose of TBI (1200 cGy in 6
ractions versus 500 cGy in 1 fraction).ith an FL-T, although considered quite refractory to
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M. Sabloff et al.962reatment may beneﬁt from ASCT and are certainly
ot hindered from pursuing alternate therapies at re-
apse. As discussed below, the nature of the disease
ay be different at relapse and more amenable to
herapy at that point.
In this study the only factors analyzed by a mul-
ivariate analysis that were signiﬁcant were age, che-
osensitivity, and a higher TBI dose with time.
The impact of TBI is interesting because although
t is known to be effective in lymphoma, it is feared
ecause of its potential for causing long-term toxicity
n the form of secondary malignancies and myelodys-
lastic syndromes (MDS) [48,49]. This issue was re-
iewed by the International Bone Marrow Transplant
egistry (IBMTR) and European Bone Marrow
ransplantation Registry (EBMTR), who indicated
hat despite its effectiveness in controlling lymphoma,
t resulted in an increased TRM [32,36]. In contrast,
ur analysis of our cohort suggests that the early
oxicity as seen in Figure 6 does not obscure the
uperior long-term survival of the higher dose of ra-
iation. However, it should be noted that differences
etween these 2 groups did exist, most of which
ere accounted for in the multivariate analysis ex-
ept for year of transplant, which is the most obvi-
us difference between the 2 groups as all the high
ose TBI was done within the ﬁrst 2 years of the
ohort. Interestingly, radiolabeled antibodies have
egun to be used in this setting and have demon-
trated a decreased TRM while preserving its effec-
iveness, so that this modality may become the pre-
erred way of delivering this part of the treatment
50]. Therefore, despite the competing risks, it ap-
ears that the beneﬁts of radiotherapy outweigh the
ong-term risks but this will have to be addressed in
uture studies.
Salvage therapy of relapse post-ASCT has been
reviously analyzed over the past decade [37,38].
ates of relapse post-ASCT were similar to our expe-
ience ranging from 33%-42%. As was described, dur-
ng the past decade, salvage of relapsed FL-NT was
onstructive, as many patients had a response to a
ariety of therapies and some had more prolonged
esponses. We also found that a variety of therapies
ie, chemotherapy, radiation, antibody-directed ther-
py, an allogeneic stem cell transplant, or node re-
oval) produced responses with some being durable.
ore recent therapies such as antibody-directed ther-
py and/or an allogeneic stem cell transplant were not
igniﬁcant in producing a remission 1 year nor were
hey predictive of long-term survival; however, these
herapies have only become either acceptable or avail-
ble late in the cohort. We may ﬁnd that they have
ore of an impact over the next decade as their wide-
pread use becomes more routine.
Finally, a similar percentage of patients died in
oth groups and have survived beyond 1 year. There-ore, despite the initial characteristics prior to relapse
nce the disease relapses after ASCT it may have
imilar characteristics regardless of the initial status
rior to ASCT (FL-NT versus FL-T) and salvaging
hese patients is feasible as they do respond to con-
entional treatments, as has also been demonstrated
y others, and a fraction can still have long-term
urvival [37,38]. However, despite improvements in
he ﬁrst-line treatments with combined modality ther-
pies the lack of improvement over the past decade in
reating those who have relapsed post ASCT is still a
ilemma [51]. We would suggest that if patients have
n acceptable performance status a trial of salvage
herapy is worthwhile, regardless of the subtype at
nitial presentation.
The toxicity of the treatment under our conditions
ppeared to be relatively mild, both short-term and
ong-term. The immediate treatment-related toxicity,
ithin the ﬁrst 100 days of the treatment and NRM of
% and 14%, respectively, is quite acceptable and in
ine with other centers [23,24,27,28,30,49,52,53]. Sec-
ndary malignancies/MDS post-treatment are always
concern and do make up the majority of the NRM
7% of 14%); however, this should be viewed in light
f the work by Johnson et al. [13], where it was found
hat within a large cohort of patients with FL who
eceived repeated courses of chemotherapy, without
n ASCT, the rate of a secondary malignancy was 5%.
herefore, although the rate of secondary malignan-
ies is higher, it is not much higher than what might
e expected had they not had an ASCT conﬁrming the
cceptability of the toxicity of such an intensive treat-
ent.
Therefore, our data suggest that an unpurged
SCT for relapsed, aggressive FL, transformed or
ot, is safe and continues to be an effective therapeutic
ool in patients who have a reasonable performance
tatus. It appears to change the natural history by
ncreasing the median survival to 16 years, and is
uperior to conventional chemotherapy at any relapse.
t also appears that some subgroups may have an
xcellent outcome such as those 40 years of age with
hemosensitive disease. Finally salvage therapy for re-
apsed disease post-ASCT is also feasible.
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